Clifford Chance

ACCC delays approval of Australian pharmaceutical code of conduct in search of greater industry transparency

5 February 2015

The Australian Competition and Consumer Commission (ACCC) has delayed the introduction of a new edition of a code of conduct for the pharmaceutical industry, expecting further amendments to provide greater transparency to industry sponsorship activities.

That transparency is likely to include mandatory reporting of payments to individual healthcare professionals, rather than the current aggregate reporting by pharmaceutical companies.

Until a new code is approved, the ACCC has temporarily extended the current edition of the Medicines Australia Code of Conduct (MACC).

Download PDF